CONCLUSION
In de novo patients with acromegaly, disease activity do not correspond to glucose homeostasis indices. However, hormonal control of GH and IGF-1 after SSA treatment is associated with reduction in HbA1c. Three months postoperatively, biochemical cure by IGF-1 and nadir GH associated with lower AUC-glucose (p=0.041) but not with fasting glucose or the reduction from baseline in both variables. For HbA1c, a possible trend towards larger reduction from baseline in patients cured after surgery, can be claimed (Table 3 ). 
RESULTS
No associations between basal IGF-1/GH levels and fasting glucose, AUCglucose or HbA1c were found. After SSA treatment, the percentage reduction in both mean GH and IGF-1 correlated positively with reduction in HbA1c levels (Table 1) . n=16 n=6
METHODS
Of the 62 de novo patients included in the POTA study, seven subjects (11 %) had impaired glucose tolerance and 12 subjects (19 %) had overt diabetes mellitus. The 55 patients with acromegaly not using antidiabetic medication were included in the present analyses. Of them, 26 received SSA for 6 months preoperatively. HbA1c and an oral glucose tolerance test (OGTT) were performed at diagnosis, before surgery and 3 months postoperatively. Area under curve of glucose (AUCglucose) was calculated. Indices of glucose homeostasis were compared between cured and non-cured patients.
